Update on romiplostim and eltrombopag indirect comparison.
University of Sheffield, UK.
Katy
K
Cooper
Amgen Ltd, Cambridge, UK.
James
J
Matcham
Amgen Ltd, Uxbridge, UK.
Kawitha
K
Helme
University of Sheffield, UK.
Ron
R
Akehurst
D001565:Benzoates / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006834:Hydrazines / Q000627:therapeutic use*; D008297:Male; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000188:drug therapy*; D011720:Pyrazoles / Q000627:therapeutic use*; D011961:Receptors, Fc / Q000627:therapeutic use*; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*; D013926:Thrombopoietin / Q000627:therapeutic use*
D001565:Benzoates; D006834:Hydrazines; D011720:Pyrazoles; D011961:Receptors, Fc; D011993:Recombinant Fusion Proteins; D013926:Thrombopoietin